source
- Crystalys Therapeutics raises $130M to launch gout drug in US and EuropeSan Diego‑based Crystalys Therapeutics announced a new $130 million Series B financing round. The capital will be used to advance its gout treatment, which already holds regulatory approval in Japa…
- Summit Therapeutics shares two-year survival data for its experimental cancer drug ivonescimab in Western patientsSummit Therapeutics presented new two-year overall survival results for its experimental antibody ivonescimab in Western participants of its global Phase 3 trial. The data were released alongside…